¼¼°èÀÇ AI ±â¹Ý µðÁöÅÐ º´¸®ÇÐ ½ÃÀå : ½Å°æ¸Áº°, ÄÄÆ÷³ÍÆ®º°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2025-2032³â)
AI-based Digital Pathology Market, By Neural Network, By Component, By Application, By End Use, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
»óǰÄÚµå : 1663438
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2025³â 01¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 381 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,702,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,728,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 8,174,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

AI ±â¹Ý µðÁöÅÐ º´¸®ÇÐ ½ÃÀå ±Ô¸ð´Â 2024³â 8,560¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2025³âºÎÅÍ 2032³â±îÁö 15.80%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î È®´ë

AI ±â¹Ý µðÁöÅÐ º´¸®ÇÐ ½ÃÀå - ½ÃÀå ¿ªÇÐ

¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡

AI ±â¹Ý µðÁöÅÐ º´¸®ÇÐ ½ÃÀåÀº °³º°È­µÈ Åõ¾à¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÇâÈÄ È®´ëµÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. °¢ ȯÀÚÀÇ ¿ä±¸, ¼±È£ ¹× Ư¡¿¡ ¸Â°Ô ÀÇ·á ¹× Ä¡·á¸¦ »ç¿ëÀÚ Á¤ÀÇÇÏ´Â °ÍÀº ¸ÂÃãÇü ÀÇ·á·Î ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù. °³ÀÎÈ­µÈ ÀÇ·á´Â °¢ ȯÀÚ °íÀ¯ÀÇ À¯ÀüÀÚ ÇÁ·ÎÆÄÀÏ, ¶óÀÌÇÁ½ºÅ¸ÀÏÀÇ ¼±ÅÃ, Áúº´ÀÇ Æ¯¼º¿¡ ¸Â°Ô Ä¡·á¹ýÀ» ¸ÂÃãÈ­ÇÔÀ¸·Î½á È¿´ÉÀ» Çâ»ó½ÃŰ°í ºÎÀÛ¿ëÀ» ÁÙÀ̱â À§ÇØ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. À¯ÀüÀÚ µ¥ÀÌÅÍ¿Í ÀÇ·á ¿µ»óÀ» º¸´Ù Á¤È®Çϰí È¿À²ÀûÀ¸·Î ºÐ¼®ÇÒ ¼ö ÀÖ°Ô ÇÔÀ¸·Î½á, AI¸¦ Ȱ¿ëÇÑ µðÁöÅÐ º´¸®Çд º¸´Ù Á¤È®ÇÑ Áø´Ü, Áúȯ ÇÏÀ§ À¯ÇüÀÇ ½Äº°, °¢ ȯÀÚ Æ¯À¯ÀÇ »ý¹°ÇÐÀû ÇÁ·ÎÆÄÀÏ¿¡ ¸ÂÃá Ä¡·á ¿ä¹ýÀÇ Ä¿½ºÅ͸¶ÀÌÁ ¿ëÀÌÇÏ°Ô ÇØ, ¸ÂÃãÇü ÀǷḦ Áö¿øÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 2¿ù ¹Ì±¹¿¡ º»»ç¸¦ µÐ Àü¹®°¡ ȸ¿ø Á¶Á÷ÀÎ Personalized Medicine CoalitionÀÌ ¹ßÇ¥ÇÑ º¸°í¼­¿¡ µû¸£¸é 2022³â¿¡´Â 12°³ÀÇ »õ·Î¿î ¸ÂÃãÇü Ä¡·áÁ¦°¡ ½ÂÀεǾúÀ¸¸ç, ÀÌ´Â Àü½Å Ä¡·áÁ¦ÀÇ ¾à 34%¿¡ ÇØ´çÇÏ¸ç ±× ÀÌÀü¿¡ ºñÇØ ÇöÀúÇÑ Áõ°¡¸¦ º¸¿©ÁÝ´Ï´Ù. ÀÌ¿Í °°ÀÌ AI ±â¹Ý µðÁöÅÐ º´¸®ÇÐ ½ÃÀåÀº ¸ÂÃãÇü Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó È®´ëµÇ°í ÀÖ½À´Ï´Ù.

AI ±â¹Ý µðÁöÅÐ º´¸®ÇÐ ½ÃÀå - ÁÖ¿ä ÀλçÀÌÆ®·Â

¿ì¸®ÀÇ ¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®°¡ °øÀ¯ÇÑ ºÐ¼®¿¡ µû¸£¸é ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2025-2032³â)¿¡ ¾à 15.80%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

½Å°æ¸ÁÀÇ ¼¼ºÐÈ­¿¡ ±âÃÊÇÏ¿©, ÄÁ¹ú·ç¼Ç ½Å°æ¸Á(CNN)Àº 2024³â ÃÖ´ë ½ÃÀå Á¡À¯À²À» ³ªÅ¸³Â½À´Ï´Ù.

¿ëµµº°·Î, ÀǾàǰÀº 2024³âÀÇ ÁÖ¿ä ºÎ¹®À̾ú½À´Ï´Ù.

ÃÖÁ¾ ¿ëµµ ¼¼ºÐÈ­¸¦ ¹ÙÅÁÀ¸·Î 2024³â¿¡´Â º´¿ø°ú ·¹ÆÛ·±½º ½ÇÇè½ÇÀÌ ÁÖ¿ä ºÎ¹®À̾ú½À´Ï´Ù.

Áö¿ªº°·Î´Â ¾Æ½Ã¾ÆÅÂÆò¾çÀÌ 2024³â ¸ÅÃâÀ» À̲ø¾ú½À´Ï´Ù.

AI ±â¹Ý µðÁöÅÐ º´¸®ÇÐ ½ÃÀå - ¼¼ºÐÈ­ ºÐ¼® :

¼¼°èÀÇ AI ±â¹Ý µðÁöÅÐ º´¸®ÇÐ ½ÃÀåÀº ½Å°æ¸Á, ÄÄÆ÷³ÍÆ®, ¿ëµµ, ÃÖÁ¾ ¿ëµµ, Áö¿ª¿¡ µû¶ó ¼¼ºÐÈ­µË´Ï´Ù.

±¸¼º ¿ä¼Ò ±â¹Ý¿¡¼­ ½ÃÀåÀº ½ºÄ³³Ê¿Í ¼ÒÇÁÆ®¿þ¾î·Î ±¸ºÐµË´Ï´Ù. 2024³â¿¡´Â ½ÃÀåÀÌ ¼ÒÇÁÆ®¿þ¾î Ä«Å×°í¸®¿¡ ÀÇÇØ Áö¹èµÇ¾ú½À´Ï´Ù. ÀÌ´Â µðÁöÅÐ º´¸®Çп¡¼­ ÀΰøÁö´É ¼ÒÇÁÆ®¿þ¾îÀÇ »ç¿ëÀÌ Áõ°¡Çϰí Àֱ⠶§¹®¿¡ º´¸®ÇÐÀÚÀÇ ½Ã°£, Á¤¹Ðµµ, °á°úÀÇ ¼Óµµ°¡ ÀúÇϵǾî, Àǻ簡 ȯÀÚÀÇ °Ç°­ »óŸ¦ Æò°¡ÇØ, ȸº¹¾àÀ» ½Å¼ÓÇÏ°Ô ½ºÄÉÁÙÇÒ ¼ö ÀÖ°Ô µÈ °ÍÀÌ ±× ¿äÀÎÀÔ´Ï´Ù. ¶ÇÇÑ, AI´Â ȯÀÚÀÇ °Ç°­ µ¥ÀÌÅ͸¦ ÀúÀåÇÏ°í °á°ú¸¦ °Ë»öÇÏ´Â µ¥ È¿°úÀûÀ¸·Î »ç¿ëµÉ ¼ö ÀÖÀ¸¸ç, Á¶»ç ±â°£ µ¿¾È AI ±â¹Ý µðÁöÅÐ º´¸®ÇÐ ¼ÒÇÁÆ®¿þ¾î¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÕ´Ï´Ù.

ÃÖÁ¾ ¿ëµµ¿¡ µû¶ó ½ÃÀåÀº º´¿ø ¹× ±âÁØ °Ë»ç½Ç, Á¦¾à ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷, Çмú±â°ü ¹× ¿¬±¸±â°üÀ¸·Î ³ª´­ ¼ö ÀÖ½À´Ï´Ù. 2024³â¿¡´Â º´¿ø ¹× ±âÁØ °Ë»ç½Ç Ä«Å×°í¸®°¡ ¾ÐµµÀûÀÎ ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. º´¿ø°ú ±âÁØ °Ë»ç½ÇÀº ¾Æ¸¶ ³¯¸¶´Ù Áõ°¡ÇÏ´Â º´¸®ÇÐ °ü·Ã »ç·Ê¸¦ ´Ù·ç°Ô µÉ °ÍÀÔ´Ï´Ù. º´¸®°Ë»çÀÇ ¾÷¹« ºÎ´ãÀÌ ´Ã¾î³²¿¡ µû¶ó ½Å·Ú¼º ³ôÀº °á°ú¸¦ ³»´Â ´É·Â°ú ½Ã°£ Àý¾à ´É·Â¿¡ ÀÇÇØ AIÀÇ ÀÌ¿ëÀÌ ÇÊ¿äÇÏ°Ô µË´Ï´Ù. ¶ÇÇÑ º´¿øÀº ÀΰøÁö´É ´öºÐ¿¡ ´õ ¸¹Àº »ç·Ê¸¦ °ü¸®ÇÏ´Â µ¥ ÇÊ¿äÇÑ º´¸® ÀÇ»çÀÇ ¼ö¸¦ ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. À̸¦ ÅëÇØ ¼¼°è AI ±â¹Ý µðÁöÅÐ º´¸®ÇÐ ½ÃÀåÀÌ ÇâÈÄ ¼ö³â°£ ¼ºÀåÇÒ ¼ö ÀÖ´Â »õ·Î¿î ±æÀ» ´õ¿í ¿­¾îÁÙ °ÍÀÔ´Ï´Ù.

AI ±â¹Ý µðÁöÅÐ º´¸®ÇÐ ½ÃÀå - Áö¸®Àû ÅëÂû

2024³â ¾Æ½Ã¾ÆÅÂÆò¾çÀº AI ±â¹Ý µðÁöÅÐ º´¸®ÇÐ Áø´Ü ¼¼°è ½ÃÀå¿¡¼­ Áö¹èÀûÀÎ ÁöÀ§¸¦ Â÷ÁöÇß½À´Ï´Ù. AI ±â¹Ý µðÁöÅÐ º´¸®ÇÐ ½ÃÀåÀº Áß±¹°ú Àεµ¿Í °°Àº ½ÅÈï ±¹°¡¿¡¼­ ÀÇ·á ºÐ¾ß¿¡¼­ AI Àû¿ëÀ» È®´ëÇÔÀ¸·Î½á È®´ëµÇ°í ÀÖ½À´Ï´Ù. NASSCOM¿¡ µû¸£¸é 2025³â±îÁö ÀεµÀÇ ÇコÄɾî AI ½ÃÀåÀº CAGR 40%·Î È®´ëµÉ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. ÀÌ´Â ÀÇ·á ºÐ¾ß¿¡¼­ AIÀÇ »ç¿ëÀÌ È®´ëµÇ°í ÀÖÀ½À» ³ªÅ¸³»¸ç ¹Ýº¹ ÀÛ¾÷À» ½Å¼ÓÇÏ°Ô ¿Ï·áÇÏ°í º´¸®ÇÐÀÇ ½Ã°£À» Àý¾àÇÒ ¼ö ÀÖÀ¸¹Ç·Î º´¸®Çп¡¼­ ÀÀ¿ëÀÌ ÃËÁøµÉ ¼ö ÀÖ½À´Ï´Ù. ÀΰøÁö´ÉÀº º´¸®ÀÇ»ç °ü·Ã ¾÷¹«ÀÇ ÀϺθ¦ ÇØ³¾ ¼ö Àֱ⠶§¹®¿¡ ÀÌ ºÐ¾ß¿¡¼­ ÇÏ±Þ º´¸®ÀÇÀÇ Á¸Àç°¡ ÇコÄÉ¾î °³¾÷ÀÇÀÇ ÀÌ¿ëÀ» µÞ¹ÞÄ§ÇØ, Á¶»ç ±â°£Áß ¼ö¿ä¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù.

±×·¯³ª ¿¹Ãø±â°£À» ÅëÇØ ºÏ¹ÌÁö¿ªÀº ¿ø°ÝÀÇ·á ÀÌ¿ëÀÌ È®´ëµÇ°í Àֱ⠶§¹®¿¡ CAGRÀÌ °¡Àå ºü¸¦ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. COVID-19´Â ¾ö°ÝÇÑ °¨±Ý ¿ä°ÇÀ¸·Î ÀÎÇØ ´ë¸é ¼¼¼Ç ´ë½Å ¿ø°Ý ÀÇ·á »ç¿ëÀ» Àå·ÁÇß½À´Ï´Ù. ¹Ì±¹ º¸°Ç»çȸ º¹Áö¼º¿¡ µû¸£¸é ¹Ì±¹ÀÇ ¸ÞµðÄÉ¾î ¼ö±ÞÀÚ´Â À¯Çà ÀÌÈÄ ¿ø°Ý ÀǷḦ ÀÚÁÖ ÀÌ¿ëÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹¿¡¼­´Â 2019³â 11¾ï °Ç¿¡¼­ 2020³â 9¾ï 8,900¸¸ °ÇÀÇ ´ë¸é Áø·á°¡ ÀÖ¾ú½À´Ï´Ù. ¿ø°ÝÁø·á ¿¹¾à °Ç¼ö´Â 2019³â 840¸¸ °Ç¿¡¼­ 2020³â 5,270¸¸ °Ç °¡±îÀÌ Áõ°¡Çß½À´Ï´Ù. °Å·¡ ºñ¿ëÀÇ °¨¼Ò·Î ÀÎÇØ Áõ°¡°¡ ¿¹»óµÇ´Â ÀÌ·¯ÇÑ µ¿ÇâÀÇ ÁøÀü¿¡ µû¶ó Àǻ簡 ¿ø°Ý Áø·á¸¦ Áö¿øÇÏ´Â AI ±â¹Ý ±â¼úÀÌ ÇÊ¿äÇÕ´Ï´Ù.

AI ±â¹Ý µðÁöÅÐ º´¸®ÇÐ ½ÃÀå - °æÀï ±¸µµ:

DoMore Diagnostics AS, Aiforia Technologies, Aiosyn, Deep Bio, F. Hoffmann-La Roche µî AI ±â¹Ý µðÁöÅÐ º´¸®ÇÐ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº ȯÀÚÀÇ °á°ú¸¦ °³¼±Çϰí, ÇÁ·Î¼¼½º¸¦ °¡¼ÓÈ­Çϰí, Áø´Ü Á¤È®µµ¸¦ ³ôÀ̱â À§ÇØ °í±Þ ¾Ï °ËÃâ Àåºñ¿Í °°Àº ÃÖ÷´Ü Á¦Ç°À» °³¹ßÇÏ´Â µ¥ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. AI¸¦ °®Ãá °í±Þ ¾Ï °ËÃâ µµ±¸´Â µö·¯´× ¸ðµ¨°ú ¸Ó½Å·¯´× ¾Ë°í¸®ÁòÀ» »ç¿ëÇÏ¿© º´¸®ÇÐ ½½¶óÀ̵å¿Í ÀÇ·á À̹ÌÁö¸¦ Æò°¡ÇÏ¿© Á¾¾ç ½Äº° ¹× ºÐ·ù Á¤È®µµ¸¦ Çâ»ó½Ãŵ´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 2¿ù Crosscope Inc.¿Í MindPeak GmbH´Â MindPeakÀÇ À̹ÌÁö ºÐ¼® µµ±¸¸¦ CrosscopeÀÇ Digital Pathology Ç÷§Æû¿¡ ÅëÇÕÇÏ¿© Á¦ÈÞÇß½À´Ï´Ù. Å©·Î½ºÄÚÇÁÀÇ AI ´É·ÂÀº ÀÌ Á¦ÈÞ¿¡ ÀÇÇØ Çâ»óµÇ¾î ¿ÏÀüÇÑ µðÁöÅÐ º´¸®ÇÐ ¼Ö·ç¼ÇÀ» Á¦°øÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÃÖ÷´Ü AI µµ±¸ÀÇ ¿øÈ°ÇÑ ÅëÇÕÀ» ÅëÇØ ÀÌ Çù¾÷Àº º´¸® Á¶Á÷ÇÐ ¿öÅ©Ç÷ο츦 °£¼ÒÈ­ÇÏ°í º´¸® Àǻ簡 ½ÇÇè½Ç »ý»ê¼ºÀ» Çâ»ó½Ã۰í ER, PR, Ki-67 IHC ºÐ¼®¿¡¼­ ºü¸£°í Áß¿äÇÑ Áø´ÜÀ» Á¦°øÇÒ ¼ö ÀÖµµ·Ï µ½°íÀÚ ÇÕ´Ï´Ù. ÅëÇÕÀÇ °á°ú, ȯÀÚÀÇ Ä¡·á ¼ºÀûÀÌ Çâ»óµÉ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

ÃÖ±Ù °³¹ß µ¿Çâ

2024³â 1¿ù: Roche´Â ¹Ì±¹ ͏®Æ÷´Ï¾ÆÁÖ ¹öŬ¸®¿¡ º»»ç¸¦ µÐ ºñ»óÀå ±â¾÷ÀÎ Carmot Therapeutics, Inc.("Carmot")¸¦ ÀμöÇÏ´Â ÇÕº´ °è¾àÀ» ÃÖÁ¾ °áÁ¤Çß´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. CarmotÀÇ R&D Æ÷Æ®Æú¸®¿À¿¡´Â ´ç´¢º´ÀÇ À¯¹«¿¡ °ü°è¾øÀÌ ºñ¸¸Áõ Ä¡·áÁ¦·Î µ¿±Þ ÃÖ°íÀÇ ÀáÀç·ÂÀ» °¡Áø ÀüÀÓ»ó½ÃÇè°ú ÀÓ»ó ´Ü°èÀÇ °æ±¸ ¹× ÇÇÇÏ ÀÎÅ©·¹Æ¾ÀÌ Æ÷ÇԵ˴ϴÙ.

2023³â 10¿ù: Ŭ¶ó¿ìµå ¼­ºñ½º Á¦°ø¾÷üÀÎ Amazon Web Services, Inc.ÀÇ Çù·ÂÀ» ÅëÇØ F. Hoffmann-La Roche Ltd.¿Í Ibex Medical Analytics Ltd.´Â AI¸¦ Ȱ¿ëÇÑ ¾Ï °ËÃâ ¼Ö·ç¼ÇÀ» Á¦°øÇϱâ À§ÇØ Á¦ÈÞÇß½À´Ï´Ù. ÀÌ Á¦ÈÞ´Â Navify Digital Pathology ¼ÒÇÁÆ®¿þ¾î Ç÷§ÆûÀ» ÅëÇØ º´¸® °Ë»ç½Ç¿¡ ¾ÆÀ̺¤½ºÀÇ AI ±¸µ¿Çü ÀÇ»ç°áÁ¤ Áö¿ø ±â´É¿¡ ´ëÇÑ ¾×¼¼½º¸¦ Á¦°øÇÕ´Ï´Ù. ÀÓ»óÀÇ´Â ÀÌ ÅëÇÕÀ» ÅëÇØ Àü¸³¼±¾ÏÀ̳ª À¯¹æ¾ÏÀÇ Áø´Ü Áö¿øÀ» ¹ÞÀ» ¼ö ÀÖ½À´Ï´Ù.

2023³â 9¿ù: À¯·´, ij³ª´Ù, ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå¿¡¼­ Hologic, Inc.¿Í Bayer AG´Â ´õ ³ªÀº À¯¹æ¾Ï ¹ß°ßÀ» À§ÇÑ Á¶¿µ À¯¹æÃÔ¿µ(CEM) ¼Ö·ç¼ÇÀ» Á¦°øÇϱâ À§ÇØ Á¦ÈÞÇß½À´Ï´Ù. Bayer¿Í HologicÀÇ ±â¼úÀ» °áÇÕÇÏ¿© À¯¹æ Á¶¿µ¼ú °Ë»ç ½Ã Á¶¿µÁ¦ Àû¿ëÀ» º¸´Ù ½±°Ô ÇÒ ¼ö ÀÖÀ» °ÍÀ¸·Î ±â´ëÇÕ´Ï´Ù. ÀÌ Á¦ÈÞ´Â ¹æ»ç¼± ±â¼úÀÚ¿¡°Ô ¿Ïº®ÇÑ Á¦Ç° ¹øµé, ½Ç¿ëÀûÀÎ Áöµµ, ºÎµå·¯¿î CEM ¿öÅ©Ç÷οì ÅëÇÕÀ» Á¦°øÇÏ´Â µ¥ ÁßÁ¡À» µÓ´Ï´Ù.

2023³â 6¿ù: ¹Ì±¹¿¡ º»»ç¸¦ µÐ µðÁöÅÐ º´¸®ÇÐ ¹× ÄÄÇ»ÆÃ º´¸® ¼Ö·ç¼Ç°ø±Þ¾÷üÀÎ Proscia Inc.´Â MindPeak GmbH¿Í Á¦ÈÞÇß½À´Ï´Ù. ÀÌ Á¦ÈÞ´Â AI¸¦ Ȱ¿ëÇÑ ¿öÅ©Ç÷ο츦 ±ä¹ÐÇÏ°Ô ¿¬°è½ÃÅ´À¸·Î½á º´¸®Àǰ¡ º¸´Ù È¿°úÀûÀ̰í Áö½ÄÀÌ Ç³ºÎÇϰí ÀçÇö¼º ÀÖ´Â ÀÓ»ó°á·Ð¿¡ µµ´ÞÇÒ ¼ö ÀÖµµ·Ï Áö¿øÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù. ±× ¸ñÀûÀº ¾Ï ȯÀÚ°¡ ´õ ³ªÀº Áø´ÜÀ»¹ÞÀ» ¼ö ÀÖµµ·ÏÇÏ´Â °ÍÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå AI ±â¹Ý µðÁöÅÐ º´¸®ÇÐ ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå AI ±â¹Ý µðÁöÅÐ º´¸®ÇÐÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå AI ±â¹Ý µðÁöÅÐ º´¸®ÇÐ »ê¾÷ ¿¬±¸

Á¦5Àå AI ±â¹Ý µðÁöÅÐ º´¸®ÇÐ ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®

Á¦6Àå AI ±â¹Ý µðÁöÅÐ º´¸®ÇÐ ½ÃÀå »óȲ

Á¦7Àå AI ±â¹Ý µðÁöÅÐ º´¸®ÇÐ ½ÃÀå - ½Å°æ¸Áº°

Á¦8Àå AI ±â¹Ý µðÁöÅÐ º´¸®ÇÐ ½ÃÀå - ÄÄÆ÷³ÍÆ®º°

Á¦9Àå AI ±â¹Ý µðÁöÅÐ º´¸®ÇÐ ½ÃÀå - ¿ëµµº°

Á¦10Àå AI ±â¹Ý µðÁöÅÐ º´¸®ÇÐ ½ÃÀå - ÃÖÁ¾ ¿ëµµº°

Á¦11Àå AI ±â¹Ý µðÁöÅÐ º´¸®ÇÐ ½ÃÀå - Áö¿ªº°

Á¦12Àå ÁÖ¿ä º¥´õ ºÐ¼®-AI ±â¹Ý µðÁöÅÐ º´¸®ÇÐ ¾÷°è

Á¦13Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

AI-based Digital Pathology Market size was valued at US$ 85.6 Million in 2024, expanding at a CAGR of 15.80% from 2025 to 2032.

AI-based digital pathology is a cutting-edge method of using digital technologies and artificial intelligence to diagnose and analyze illnesses. In order to identify patterns, anomalies, and particular disease signs, pathology slides are digitized into high-resolution images and subsequently sent to AI algorithms for analysis. By automating repetitive procedures, increasing diagnostic precision, and spotting minute details that would be overlooked during manual inspection, these AI systems might help pathologists. The AI-based digital pathology market is growing as a result of the growing emphasis on hospital cost control and efficiency enhancement, the rising need for technologically sophisticated solutions, and the rising number of incorrect diagnoses. Additionally, it is anticipated that government-funded research initiatives that support the creation of cutting-edge digital tools for pathology would support the AI-based digital pathology market growth.

AI-based Digital Pathology Market- Market Dynamics

Growing demand for personalized medication

The market for AI-based digital pathology is anticipated to increase in the future due to the growing demand for personalized medication. Customizing medical care and treatment to each patient's unique needs, preferences, and traits is known as personalized medicine. Personalized medicine is becoming more and more necessary in order to improve efficacy and decrease side effects by customizing therapies to each patient's unique genetic profile, lifestyle choices, and illness features. By making it possible to analyze genetic data and medical images more accurately and efficiently, AI-based digital pathology supports personalized medicine by facilitating more precise diagnosis, improved identification of disease subtypes, and customized treatment regimens that fit each patient's particular biological profile. For instance, a report released in February 2023 by the US-based professional membership organization Personalized Medicine Coalition stated that the approval of 12 new personalized medications in 2022-roughly 34% of all new therapies-represented a notable increase over prior years. Thus, the market for AI-based digital pathology is expanding due to the growing demand for tailored therapy.

AI-based Digital Pathology Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 15.80% over the forecast period (2025-2032)

Based on neural network segmentation, the convolutional neural networks (CNNs) were predicted to show maximum market share in the year 2024

Based on application segmentation, drug discovery was the leading segment in 2024

Based on end use segmentation, hospitals & reference laboratories were the leading segment in 2024

On the basis of region, Asia-Pacific was the leading revenue generator in 2024

AI-based Digital Pathology Market- Segmentation Analysis:

The Global AI-based Digital Pathology Market is segmented on the basis of Neural Network, Component, Application, End Use, and Region.

On the basis of component, the market is segregated into Scanners and Software. In 2024, the market was dominated by the software category due to the increasing use of artificial intelligence software in digital pathology, which has been fueled by a decrease in pathologists' time, accuracy, and speed of results, enabling physicians to assess a patient's health and schedule recovery medication rapidly. Additionally, AI may be used effectively to store patient health data and retrieve results, which will increase the demand for AI-based digital pathology software during the study period.

Based on end use, the market is divided into Hospitals & Reference Laboratories, Pharmaceutical & Biotechnology Companies, and Academic & Research Institutes. In 2024, the hospitals & reference laboratories category held a dominant market share. Hospitals and reference labs will probably deal with an increasing number of pathology-related cases every day. The increasing burden for pathology jobs will need the use of AI due to its ability to produce reliable results and its time-saving capabilities. Additionally, hospitals can reduce the number of pathologists they require to manage more cases thanks to AI. This will further open up new avenues for the global AI-based digital pathology market to grow in the years to come.

AI-based Digital Pathology Market- Geographical Insights

In 2024, Asia-Pacific held a dominant position in the global market for AI-based Digital Pathology. The market for AI-based digital pathology is expanding due to the expanding application of AI in healthcare sectors in developing nations like China and India. By 2025, the healthcare AI market in India is anticipated to expand at a 40% CAGR, according to NASSCOM. This illustrates the growing usage of AI in the medical field, which could encourage its application in pathology due to its speedy completion of repetitive tasks and capacity to save pathologists time. Because artificial intelligence can do some pathologist-related duties, the presence of lower-level pathologists in the area is pushing healthcare practitioners to use it, increasing demand for it during the research period.

However, throughout the projected period, the North America region is anticipated to see the fastest CAGR because of the growing use of telemedicine. Due to strict lockdown requirements, COVID-19 encouraged the use of telemedicine instead of in-person sessions. Medicare beneficiaries in the US have been using telemedicine more frequently since the epidemic, according to the US Department of Health and Human Services. In the United States, there were 989 million in-person medical visits in 2020, up from 1.1 billion in 2019. By 2020, there were almost 52.7 million telemedicine appointments, up from 8,40,000 in 2019. AI-based technologies that assist physicians in treating patients remotely will be required as this trend, which is anticipated to increase due to decreased transaction costs, develops.

AI-based Digital Pathology Market- Competitive Landscape:

Leading players in the AI-based digital pathology market, such as DoMore Diagnostics AS, Aiforia Technologies, Aiosyn, Deep Bio, F. Hoffmann-La Roche, and others, are concentrating on creating cutting-edge products, such as sophisticated cancer detection instruments to boost patient outcomes, expedite processes, and increase diagnostic precision. AI-powered advanced cancer detection tools use deep learning models and machine learning algorithms to evaluate pathology slides and medical images, improving the precision of tumour identification and classification. For instance, in February 2022, Crosscope Inc. and MindPeak GmbH partnered to include MindPeak's image analysis tools into Crosscope's Digital Pathology platform. Crosscope's AI capabilities are improved by this collaboration, allowing them to offer complete digital pathology solutions. Through the smooth integration of cutting-edge AI tools, the collaboration seeks to streamline Histopathology workflows, assisting pathologists in enhancing lab productivity and providing prompt and significant diagnoses for ER, PR, and Ki-67 IHC analysis. Treatment outcomes for patients are expected to improve as a result of the integration.

Recent Development

January 2024: Roche declared that it had finalized a merger deal to buy Berkeley, California-based Carmot Therapeutics, Inc. ("Carmot"), a privately held US business. Carmot's research and development portfolio includes a range of preclinical studies and clinically staged oral and subcutaneous incretins with best-in-class potential to treat obesity in individuals with and without diabetes.

October 2023: With the help of cloud service provider Amazon Web Services, Inc., F. Hoffmann-La Roche Ltd. and Ibex Medical Analytics Ltd. have partnered to offer AI-powered cancer detection solutions. Through the Navify Digital Pathology software platform, this partnership seeks to provide pathology labs with access to Ibex's AI-driven decision support capabilities. Clinicians can get help diagnosing prostate and breast cancer through this integration.

September 2023: In the European, Canadian, and Asia Pacific markets, Hologic, Inc. and Bayer AG have teamed together to offer contrast-enhanced mammography (CEM) solutions for better breast cancer detection. By combining Bayer and Hologic's technology, the alliance hopes to make it easier to apply contrast media during mammography exams. The collaboration is centred on offering radiologists complete product bundles, practical instruction, and smooth CEM workflow integration.

June 2023: Proscia Inc., a U.S.-based supplier of digital and computational pathology solutions, has partnered with MindPeak GmbH. Through closely coordinated AI-powered workflows, this collaboration seeks to assist pathologists in reaching more effective, knowledgeable, and repeatable clinical conclusions. The objective is to increase cancer patients' access to better diagnostics.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL AI-BASED DIGITAL PATHOLOGY MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

GLOBAL AI-BASED DIGITAL PATHOLOGY MARKET, BY NEURAL NETWORK- MARKET ANALYSIS, 2019 - 2032

GLOBAL AI-BASED DIGITAL PATHOLOGY MARKET, BY COMPONENT- MARKET ANALYSIS, 2019 - 2032

GLOBAL AI-BASED DIGITAL PATHOLOGY MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

GLOBAL AI-BASED DIGITAL PATHOLOGY MARKET, BY END USE- MARKET ANALYSIS, 2019 - 2032

GLOBAL AI-BASED DIGITAL PATHOLOGY MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

Table of Contents

1. AI-based Digital Pathology Market Overview

2. Executive Summary

3. AI-based Digital Pathology Key Market Trends

4. AI-based Digital Pathology Industry Study

5. AI-based Digital Pathology Market: COVID-19 Impact Analysis

6. AI-based Digital Pathology Market Landscape

7. AI-based Digital Pathology Market - By Neural Network

8. AI-based Digital Pathology Market - By Component

9. AI-based Digital Pathology Market - By Application

10. AI-based Digital Pathology Market - By End Use

11. AI-based Digital Pathology Market- By Geography

12. Key Vendor Analysis- AI-based Digital Pathology Industry

13. 360 Degree Analyst View

14. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â